Patents by Inventor Edward Ruediger

Edward Ruediger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20070078141
    Abstract: This disclosure provides compounds of Formula I as described herein having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the disclosure is concerned with indole and azaindole piperazine diamide derivatives that possess unique antiviral activity. More particularly, the present disclosure relates to compounds useful for the treatment of HIV and AIDS.
    Type: Application
    Filed: October 2, 2006
    Publication date: April 5, 2007
    Inventors: Tao Wang, John Kadow, Nicholas Meanwell, Zhongxing Zhang, Zhiwei Yin, Clint James, Edward Ruediger, Bradley Pearce
  • Publication number: 20060025403
    Abstract: Compounds having the formula (I), and pharmaceutically-acceptable salts, hydrates and prodrugs thereof, in which E is X is N or CH, W is —NR16R17, —NR16C(?O)R22, —NR16CO2R22, —OR23, or a heteroaryl or heterocyclo group as defined in the specification, and R1 through R12, R16, R17, R22, R23, x, y, and z are as defined in the specification, are useful as modulaters of melanocortin receptors, particularly MC-1R and MC-4R.
    Type: Application
    Filed: August 8, 2005
    Publication date: February 2, 2006
    Inventors: Guixue Yu, John Macor, Timothy Herpin, R. Lawrence, George Morton, Rejean Ruel, Graham Poindexter, Edward Ruediger, Carl Thibault
  • Publication number: 20060014745
    Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The compounds of the invention inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
    Type: Application
    Filed: June 21, 2005
    Publication date: January 19, 2006
    Inventors: Ashvinikumar Gavai, Harold Mastalerz, Jean-Paul Daris, Pierre Dextraze, Philippe Lapointe, Edward Ruediger, Dolatrai Vyas, Guifen Zhang
  • Publication number: 20050267130
    Abstract: The invention encompasses a series of tetrahydrocarboline compounds of Formula I which inhibit HIV entry by attaching to the exterior viral envelop protein gp120 and interrupting the viral entry process, possibly by interfering with the cellular receptor CD4. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.
    Type: Application
    Filed: May 20, 2005
    Publication date: December 1, 2005
    Inventors: Edward Ruediger, Daniel Deon, John Kadow
  • Publication number: 20050197339
    Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The compounds of the invention inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents for the treatment of cancer and other diseases.
    Type: Application
    Filed: December 22, 2004
    Publication date: September 8, 2005
    Inventors: Ashvinikumar Gavai, Wen-Ching Han, Ping Chen, Edward Ruediger, Harold Mastalerz, Brian Fink, Derek Norris